FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
DMB Number:	3235-0287				
Estimated average burden					
ours per respon	se 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)		*	2 Igguer Name a	nd Tieleen	or Tro-	ling C-	mbol		5 Relation	nshin of Re	norting Person	n(s) to Issue	r
* 0				2. Issuer Name and Ticker or Trading Symbol ACCESS PHARMACEUTICALS INC [ACCP]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) ACCESS PHARMAC STEMMONS FRWY		(Middle) NC, 2600	3. Date of Earliest Transaction (Month/Day/Year) 01/23/2012				X Officer (give title below) Other (specify below) CFO			elow)			
DALLAS, TX 752072	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City)	(State)	(Zip)	Tab	ole I - Non-	-Deriva	ative S	ecurities A	Acqui	red, Disp	osed of, or	Beneficially (Owned	
1.Title of Security (Instr. 3)	Date		2A. Deemed Execution Date, if	3. Transa Code (Instr. 8)	action 4	A. Secur (A) or I (D)	rities Acqu Disposed of	quired 5. Amount of S of Beneficially O Reported Tran		Amount of Securities eneficially Owned Following eported Transaction(s)		6. 7. Nature Ownership Form: Beneficial Direct (D) Ownership	
				Code	V	Amoun	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common stock	01/2	23/2012		A	1	15,000	A \$.36	18,521			D	
Reminder: Report on a se indirectly.		Table II - D	Derivative Securition 2.g., puts, calls, wan	es Acquire	Person contain the for	ined ir rm dis posed o	n this form splays a coor, of, or Bene	m are curre eficial	e not req ntly valid	uired to re d OMB co	nformation espond unle ntrol numbe	ess	C 1474 (9- 02)
1. Title of Derivative Conversion Date Execution Execution Conversion Of Exercise (Month/Day/Year)		any	tte, if Transaction Code Year) (Instr. 8)		and Ex			Amo Und Secu (Inst 4)	Title and mount of derlying curities listr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ownershi Form of Derivative Security: Direct (Dor Indirect	(Instr. 4)
							Date	Title	Number of Shares				
					Date Exerci		Expiration Date	Title	Number of				

Donatic October Vision (Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
THOMPSON STEPHEN B ACCESS PHARMACEUTICALS INC 2600 STEMMONS FRWY STE 176 DALLAS, TX 752072107			CFO			

Signatures

Stephen B. Thompson	01/26/2012
***Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.